Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease (MRD) Testing By Next Generation Sequencing (NGS) after Two Cycles (CY) of Non-Intensive Chemoimmunotherapy Is Predictive of Remission Duration and Need for Maintenance Therapy (MT) in Previously Untreated Mantle Cell Lymphoma (MCL): A Wisconsin Oncology Network Study

Danielle McQuinn, Meredith Hyun, KyungMann Kim, Vaishalee P Kenkre, Christopher D Fletcher, Saurabh A Rajguru, Priyanka A Pophali, Mariah Endres, Mitch Howard, Tim Wassenaar, Ruth Callaway Warren, Ryan J Mattison, Kari B Wisinski, Julie E Chang

Blood (2023) 142 (Supplement 1): 4407.

https://doi.org/10.1182/blood-2023-173871

Published: 2023

Journal Articles

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Julie E Chang, MD, Vaishalee P. Kenkre, MD, Christopher D. Fletcher, MD, Aric C. Hall, MD, Natalie Scott Callander, MD, Kyungmann Kim, PhD, Grace Yi Chen, Kaitlin Chambers

Blood (2019) 134 (Supplement_1): 5470.

https://doi.org/10.1182/blood-2019-124489

Published: 2019

Journal Articles

A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies

Christopher R. D'Angelo, MD, Aric C. Hall, MD, Kyungmann Kim, PhD, Ryan J. Mattison, MD, Walter L. Longo, MD, Peiman Hematti, MD, Natalie Scott Callander, MD, Mark Juckett, MD

Blood (2018) 132 (Supplement 1): 2107.

https://doi.org/10.1182/blood-2018-99-112670

Published: 2018

Journal Articles

Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study

Julie E. Chang, MD, Christopher Peterson, MD, Lakeesha L. Carmichael, MS, KyungMann Kim, PhD, David T. Yang, MD, Anne M. Traynor, MD, Jae E. Werndli, BSc, MSc, Michael Huie, MD, Thomas McFarland, MD, Michael Volk, MD, Jules H. Blank, MD, Natalie S. Callander, MD, Walter L. Longo, MD, Brad S. Kahl, MD

Blood (2016) 128 (22): 149.

https://doi.org/10.1182/blood.V128.22.149.149

Published: 2016

Journal Articles

Initial Results of an Ex Vivo Microfluidic Cis -Coculture Csra to Predict Response for Myeloma Patients

Chorom Pak, PhD, Natalie S Callander, MD, Edmond WK Young, PhD, Benjamin Titz, PhD, KyungMann Kim, PhD, Kenny Chng, BA, Shigeki Miyamoto, PhD, David J Beebe, PhD

Blood (2014) 124 (21): 4706.

https://doi.org/10.1182/blood.V124.21.4706.4706

Published: 2014

Journal Articles

Weekly Temsirolimus and Bortezomib For Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma: A Wisconsin Oncology Network Phase II Study

Timothy S. Fenske, MD, KyungMann Kim, PhD, Chong Zhang, MS, John P. Farnen, MD, FACP, Adedayo A. Onitilo, MD, Jules H. Blank, MD, Harish Ahuja, MD, Tim Wassenaar, MD, Rubina Qamar, MD, Patrick Mansky, MD, Anne Traynor, MD, Ryan J. Mattison, MD, Brad S. Kahl, MD

Blood (2013) 122 (21): 3035.

https://doi.org/10.1182/blood.V122.21.3035.3035

Published: 2013

Journal Articles

Specific KIR and HLA Genotypes Affect Outcomes Of Single-Agent Anti-CD20 Immunotherapy Of Follicular Lymphoma

Bartosz Grzywacz, MD, Amy K Erbe, PhD, Wei Wang, BS, Erik A. Ranheim, MD, PhD, Jacquelyn A Hank, PhD, KyungMann Kim, PhD, Lakeesha Carmichael, MS, Songwon Seo, MS, Eneida A Mendonca, MD, PhD, Yiqiang Song, MS, Fangxin Hong, PhD, Randy D. Gascoyne, MD, Elisabeth Paietta, PhD, Sandra J. Horning, MD, Brad S. Kahl, MD, Paul M Sondel, MD, PhD

Blood (2013) 122 (21): 507.

https://doi.org/10.1182/blood.V122.21.507.507

Published: 2013

Journal Articles

Bendamustine + Rituximab (BR) Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Wisconsin Oncology Network (WON) Study

Blood (2012) 120 (21): 3647.

https://doi.org/10.1182/blood.V120.21.3647.3647

Published: 2012

Journal Articles

Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma

Andrew T Humbert, Rachel Cook, MS, MD, Thomas McFarland, Ronald Go, MD, Stephanie Markovina, MD, Shigeki Miyamoto, PhD, Eliot C. Williams, MD, PhD, Fotios Asimakopoulos, MBBChir, PhD, Jill Kolesar, PhD, Michael A. Thompson, MD, PhD, Kyungmann Kim, Natalie Callander, MD

Blood (2012) 120 (21): 5041.

https://doi.org/10.1182/blood.V120.21.5041.5041

Published: 2012

Journal Articles

Expression of the Bcl-2 Family of Regulatory Proteins by Quantitative Immunohistochemistry (AQUA) in Follicular Lymphoma.

Julie E Chang, MD, Songwon Seo, Kyungmann Kim, PhD, Adam M Petrich, MD, David T Yang, MD, Christopher Peterson, MD, Brad S Kahl, MD, Michelle A Waknitz, Catherine P Leith, MBBChir

Blood (2009) 114 (22): 4996.

https://doi.org/10.1182/blood.V114.22.4996.4996

Published: 2009

Journal Articles

The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317).

Natalie Scott Callander, MD, Stephanie Markovina, BA, Mark B. Juckett, MD, Elizabeth Wagner, MA, Jill Kolesar, Walter Longo, Eliot C. Williams, MD, PhD, Kyungmann Kim, Jae Werndli, BSc, MSc, Shigeki Miyamoto, PhD

Blood (2009) 114 (22): 3885.

https://doi.org/10.1182/blood.V114.22.3885.3885

Published: 2009

Journal Articles

Phase II Study of Arsenic Trioxide Plus Ascorbic Acid for Relapsed and Refractory Lymphoid Malignancies: A Wisconsin Oncology Network Study.

Brad S. Kahl, MD, Harish G. Ahuja, MD, Federico A. Sanchez, MD, Gilberto A. Rodrigues, MD, Peter M. Voorhees, MD, Emily A. Stevens, Jamie Smith, Nancy Turman, KyungMann Kim, Ph.D, Howard H. Bailey, MD

Blood (2004) 104 (11): 4582.

https://doi.org/10.1182/blood.V104.11.4582.4582

Published: 2004

NARROW

Minimal Residual Disease (MRD) Testing By Next Generation Sequencing (NGS) after Two Cycles (CY) of Non-Intensive Chemoimmunotherapy Is Predictive of Remission Duration and Need for Maintenance Therapy (MT) in Previously Untreated Mantle Cell Lymphoma (MCL): A Wisconsin Oncology Network Study

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies

Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study

Initial Results of an Ex Vivo Microfluidic Cis -Coculture Csra to Predict Response for Myeloma Patients

Weekly Temsirolimus and Bortezomib For Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma: A Wisconsin Oncology Network Phase II Study

Specific KIR and HLA Genotypes Affect Outcomes Of Single-Agent Anti-CD20 Immunotherapy Of Follicular Lymphoma

Bendamustine + Rituximab (BR) Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Wisconsin Oncology Network (WON) Study

Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma

Expression of the Bcl-2 Family of Regulatory Proteins by Quantitative Immunohistochemistry (AQUA) in Follicular Lymphoma.

The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317).

Phase II Study of Arsenic Trioxide Plus Ascorbic Acid for Relapsed and Refractory Lymphoid Malignancies: A Wisconsin Oncology Network Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only